Dasatinib, prednisone, and blinatumomab combination shows promising outcomes in elderly patients with Ph+ ALL

Blinatumomab plus chemotherapy shows manageable toxicity in adults with Ph- B-ALL

Tucatinib added to trastuzumab and pertuzumab improves PFS in first-line HER2-positive metastatic breast cancer

Pirtobrutinib significantly improves PFS in treatment-naïve CLL/SLL compared to bendamustine plus rituximab

Longer follow-up shows promising PFS + MRD negativity for mosunetuzumab use in untreated high tumour burden follicular lymphoma

Rusfertide provides durable control of haematocrit and phlebotomy reduction in polycythemia vera

Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL

MRD validated as a surrogate endpoint for survival in AML

Complement-bound procoagulant platelets predict thrombosis in antiphospholipid syndrome

IP6K1-driven tumour polyphosphate may contribute to immune checkpoint inhibitor-associated thrombosis

Exploring genomic insights in acute lymphoblastic leukaemia treatment

AI and pathology reveal higher late recurrence risk in invasive lobular breast cancer